231 related articles for article (PubMed ID: 27430283)
21. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Feldman ME; Shokat KM
Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
[TBL] [Abstract][Full Text] [Related]
22. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
23. Blockade of epidermal growth factor receptor/mammalian target of rapamycin pathway by Icariside II results in reduced cell proliferation of osteosarcoma cells.
Geng YD; Yang L; Zhang C; Kong LY
Food Chem Toxicol; 2014 Nov; 73():7-16. PubMed ID: 25119583
[TBL] [Abstract][Full Text] [Related]
24. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
Tomek K; Wagner R; Varga F; Singer CF; Karlic H; Grunt TW
Mol Cancer Res; 2011 Dec; 9(12):1767-79. PubMed ID: 21970855
[TBL] [Abstract][Full Text] [Related]
25. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.
Sekulić A; Hudson CC; Homme JL; Yin P; Otterness DM; Karnitz LM; Abraham RT
Cancer Res; 2000 Jul; 60(13):3504-13. PubMed ID: 10910062
[TBL] [Abstract][Full Text] [Related]
26. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
27. Caffeine induces apoptosis of osteosarcoma cells by inhibiting AKT/mTOR/S6K, NF-κB and MAPK pathways.
Miwa S; Sugimoto N; Yamamoto N; Shirai T; Nishida H; Hayashi K; Kimura H; Takeuchi A; Igarashi K; Yachie A; Tsuchiya H
Anticancer Res; 2012 Sep; 32(9):3643-9. PubMed ID: 22993301
[TBL] [Abstract][Full Text] [Related]
28. miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway.
Zhang X; Shi H; Tang H; Fang Z; Wang J; Cui S
Int J Mol Med; 2015 May; 35(5):1301-8. PubMed ID: 25760926
[TBL] [Abstract][Full Text] [Related]
29. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance.
Khamzina L; Veilleux A; Bergeron S; Marette A
Endocrinology; 2005 Mar; 146(3):1473-81. PubMed ID: 15604215
[TBL] [Abstract][Full Text] [Related]
30. LY294002 inhibits the malignant phenotype of osteosarcoma cells by modulating the phosphatidylinositol 3‑kinase/Akt/fatty acid synthase signaling pathway in vitro.
Zhou Y; Zhu LB; Peng AF; Wang TF; Long XH; Gao S; Zhou RP; Liu ZL
Mol Med Rep; 2015 Feb; 11(2):1352-7. PubMed ID: 25351625
[TBL] [Abstract][Full Text] [Related]
31. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
[TBL] [Abstract][Full Text] [Related]
32. Phosphorylated mTOR expression correlates with podoplanin expression and high tumor grade in esophageal squamous cell carcinoma.
Chuang WY; Chang YS; Chao YK; Yeh CJ; Ueng SH; Chang CY; Liu YH; Tseng CK; Chang HK; Wan YL; Hsueh C
Int J Clin Exp Pathol; 2015; 8(10):12757-65. PubMed ID: 26722465
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
Anderson JL; Park A; Akiyama R; Tap WD; Denny CT; Federman N
PLoS One; 2015; 10(9):e0133610. PubMed ID: 26402468
[TBL] [Abstract][Full Text] [Related]
34. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
[TBL] [Abstract][Full Text] [Related]
35. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Bartalucci N; Guglielmelli P; Vannucchi AM
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
[TBL] [Abstract][Full Text] [Related]
36. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
[TBL] [Abstract][Full Text] [Related]
37. Targeting the mTOR pathway using deforolimus in cancer therapy.
Mahalingam D; Sankhala K; Mita A; Giles FJ; Mita MM
Future Oncol; 2009 Apr; 5(3):291-303. PubMed ID: 19374536
[TBL] [Abstract][Full Text] [Related]
38. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Bitting RL; Armstrong AJ
Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
[TBL] [Abstract][Full Text] [Related]
39. Estrogen receptor β induces autophagy of osteosarcoma through the mTOR signaling pathway.
Yang Z; Yu W; Liu B; Yang M; Tao H
J Orthop Surg Res; 2020 Feb; 15(1):50. PubMed ID: 32054506
[TBL] [Abstract][Full Text] [Related]
40. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
